Palisade Bio Completes Microbiome Study Confirming Bacterial Enzymes For Local Bioactivation Of Lead Product Candidate, PALI-2108, Advancing Toward Commencement Of Phase 1 Human Clinical Study Of PALI-2108 For The Treatment Of UC Before Year End
Portfolio Pulse from Benzinga Newsdesk
Palisade Bio (NASDAQ:PALI) has completed a microbiome study confirming the presence of bacterial enzymes for the local bioactivation of its lead product candidate, PALI-2108. The company is advancing towards a Phase 1 human clinical study for the treatment of ulcerative colitis (UC) before the end of the year.
July 29, 2024 | 12:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Palisade Bio has completed a microbiome study confirming the presence of bacterial enzymes for the local bioactivation of its lead product candidate, PALI-2108. The company is advancing towards a Phase 1 human clinical study for the treatment of ulcerative colitis (UC) before the end of the year.
The successful completion of the microbiome study and the advancement towards Phase 1 human clinical trials for PALI-2108 is a positive development for Palisade Bio. This progress could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100